Document:

EXHIBIT
10.41 

   

 Amended
Bridge Debt Financing Agreement 

   

 This
Amended Bridge Debt Financing Agreement, dated as of this 1st day of June 1, 2019 (the “Agreement”), effective
as of November 1, 2018, is by and between Accelerated Pharma, Inc., a Delaware corporation with offices located at 15W155 81st
Street, Burr Ridge, IL 60507 (the “Borrower”), on the one hand, and one or more lenders whose signature are attached
on Schedule A hereto, (each a “Lender” and collectively, the “Lenders). 

   

 WHEREAS,
the Borrower desires to borrow from the Lenders funds for the purpose of bridge financing pursuant to the terms of this Agreement
(the “Loan(s)”) the purpose of which is to fund the business operations of the Borrower during the period while the
Borrower’s registration statement on Form S-1, file no. 333- 227916, filed with the United States Securities and Exchange
Commission (the “SEC”) on October 22, 2018 and amended on January 25, 2019 (the “Registration Statement”)
is pending; and 

   

 WHEREAS,
the Borrower and Lenders understand that pursuant to the terms of the Registration Statement, the Borrower is offering a total
of 750,000 units (the “Units”), each Unit consisting of one (1) share of our Common Stock (the “Shares”)
and one (1) Class A Warrant (the “Warrants”), exercisable on or before the five-year anniversary of issuance to purchase
one (1) additional Share at an exercise price of $4.40 per Share (the “Warrant Exercise Price”) for a total offering
of $3,000,000 (the “Offering”); and 

   

 WHEREAS,
the Borrower and Lenders acknowledges that the Lenders began funding the Loans in November 2018 and have continued to fund Loans
to dated, which at or about May 2019 totaled approximately $227,000, and which Loans may continue to increase while the Registration
Statement is pending (hereinafter, the “Loan Amount”); and 

   

 WHEREAS,
the Borrower agrees that as further inducement for Lender(s) to entering into the Loan, the Borrower has agreed to issue to the
Lender(s) or Lenders’ designee(s) Class B Warrants (the “Class B Warrants”) which are identical to the Class
A Warrants included as part of the Units subject to the Registration Statement, except that the Class B Warrants are exercisable
for a period of three (3) years from the effective date of the Registration Statement and the Borrower and Lenders further agree
that 12,500 Class B Warrants shall be issued for each $50,000 of the Loan funded under this Agreement, which Class B Warrants
shall be issued in the names of the Lenders based upon the amount of the Loan funded by each Lender and shall be allocated among
the Lenders based upon their respective participation in the Loan Amount; and 

   

 WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933,
as amended (the “Act”), and Rule 506 promulgated thereunder by the SEC, the Borrower desires to issue and sell to
the Lender, and the Lender desires to purchase from the Borrower the securities evidenced by the Loan and the Class B Warrants
upon the terms and subject to the limitations and conditions set forth in this Agreement. 

   

 Section
1. Payment. The principal amount of this Loan together with accrued and unpaid interest at the rate of 6% per annum (the “Interest”)and
all other charges, costs and expenses, is due and payable to the Lender or Lender’s designee(s) on the earlier of: (i) August
31, 2019; or (ii) the receipt by the Borrower of proceeds from the Registration Statement of at least $500,000. All payments under
this Agreement are applied first to accrued Interest and then to the balance of the outstanding Loan Amount. 

   

 Section
2. Prepayment. The Borrower has the right to prepay all or any part of the Loan Amount of , together with accrued and unpaid
Interest thereon, at any time without prepayment penalty or premium of any kind. 

   

    	 	 	 

    	 

    

   

 Section
3. Borrower’s Representations.  

   

 (a)
Organization and Qualification: The Borrower and each of its subsidiaries, if any, is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate
and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated
and conducted. 

   

 (b)
Authorization; Enforcement. (i) The Borrower has all requisite corporate power and authority to enter into and perform
this Agreement and the Loan and to consummate the transactions contemplated hereby and thereby and to issue the Shares, in accordance
with the terms hereof and thereof, (ii) the execution and delivery of this Agreement and the Loan and the issuance of the Shares
by the Borrower and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by the
Borrower’s Board of Directors and no further consent or authorization of the Borrower, its Board of Directors, or any other
party or persons is required, (iii) this Agreement has been duly executed and delivered by the Borrower by its authorized representative,
and such authorized representative is the true and official representative with authority to sign this Agreement and the other
documents executed in connection herewith and bind the Borrower accordingly, and (iv) this Agreement constitutes, and upon execution
and delivery by the Borrower of this Agreement and the Shares will constitute, a legal, valid and binding obligation of the Borrower
enforceable against the it in accordance with its terms. 

   

 Section
4. Costs and Fees. In the event of default, the Borrower shall pay to the Lender all costs of collection including reasonable
attorney’s fees in connection with the enforcement of this Agreement and the collection of the Loan. 

   

 Section
5. Waiver. The Borrower waives presentment, protest and demand, notice of protest, demand and dishonor and nonpayment of this
Loan. 

   

 Section
6. Successors and Assigns. This Agreement will inure to the benefit of and be binding on the respective successors and permitted
assigns of the Borrower. The Borrower may not assign its rights or delegate its duties under this Agreement without the Lender’s
prior written consent. 

   

 Section
7. Amendment. This Agreement may be amended or modified only by a written agreement signed by the Borrower and Lender. 

   

 Section
8. Severability. In the event that any of the provisions of this Agreement and Loan are held to be invalid or unenforceable
in whole or in part, the remaining provisions shall not be affected and shall continue to be valid and enforceable as though the
invalid or unenforceable parts had not been included in 

 this
Agreement and Loan. 

   

 Section
9. Notifications. Any notice or communication under this Agreement or the transactions contemplated hereby must be in writing
and the Parties shall give all notices and communications between the Parties in writing by: (i) personal delivery; (ii) a nationally-recognized,
next-day courier service; (iii) first- class registered or certified mail, postage prepaid; (iv) electronic mail to the Party’s
address designated in separate written instruction or to the address that a Party has notified to be that Party’s address
for the purposes of this section. 

   

 Section
10. Go v erning La w. Thi s Lo an s h all b e go v ern ed by an d co ns tru ed i n accordance with the laws of the State of
New York, without regard to the principles of conflicts of laws. Any action brought by either Party against the other Party concerning
the transactions contemplated by this Agreement shall be brought only in a court of competent jurisdiction in New York County,
State of New York. The Borrower hereby irrevocably waives any right it may have to, and agrees not to request, a jury trial for
the adjudication of any dispute hereunder or in connection with or arising out of this note or any transaction contemplated hereby. 

   

 (Signatures
on Following Page) 

   

    	 	 	 

    	 

    

   

 IN WITNESS
WHEREOF,
the undersigned
has executed
this Agreement
as of the date
first
stated
above. 

   

 Accelerated Pharma, Inc. (Borrower) 

   

	 By: 	 Michael
    Fonstein 	   
	 Name: 	 Michael Fonstein 	   
	 Title: 	 Chief Executive Officer 	   

   

    	 	 	 

    	 

    

   

 SCHEDULE A 

 LENDERSTHIS
NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE
OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION
OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT.

 

MATEON
THERAPEUTICS, INC.

 

CONVERTIBLE
PROMISSORY NOTE

 

	US$200,000	July
    22nd, 2019

 

FOR
VALUE RECEIVED, MATEON THERAPEUTICS, INC., a corporation duly incorporated under the laws of the State of Delaware (the “Company”),
hereby promises to pay to POINTR DATA INC., or its permissible assigns (the “Holder”) the principal sum of
$200,000.00, together with accrued and unpaid interest thereon, in the manner provided herein. This convertible promissory note
(this “Note”) is being issued by the Company to the original Holder of this Note (the “Original Holder”)
pursuant to that certain Note Purchase Agreement dated as of July 22nd, 2019 by and between the Company and the Original Holder
(the “Purchase Agreement”). Each capitalized term used, but not defined, in this Note shall have the meaning
ascribed to it in the Purchase Agreement.

 

1.
Payment.

 

(a)
Payment. Unless earlier converted as provided herein, all amounts outstanding and unpaid under this Note shall be due and
payable on the earliest to occur of: (i) at the Company’s election or on demand by the Holder at any time on or after January
1, 2020 or (ii) on demand by the Holder at any time following an Event of Default (the earliest to occur of clauses (i) or (ii)
being referred to herein as the “Maturity Date”). The Company waives demand, presentment, diligence, protest,
notice of protest and notice of dishonor with respect to this Note. All payments will be made in lawful money of the United States
of America at the principal office of the Company, or at such other place as the Holder may from time to time designate in writing
to the Company.

 

(b)
Pre-Payment. This Note may be prepaid at the election of the Company and the prior written consent of the Holder at any
time without penalty upon five (5) days prior written notice to the Holder.

 

    	 	 	 

    	 

    

 

2.
Interest. Interest on the unpaid principal amount shall accrue beginning on the issue date set forth above at a rate
equal to eight percent (8.0%) per annum computed on the basis of the actual number of days elapsed and a year of 365 days from
the date of this Note until the principal amount and all interest accrued thereon are paid or converted as provided in Section
3 hereof. Except upon the earlier conversion in accordance with Section 3, interest be due and payable on a monthly basis
on the 15th day of each such month (or the next business day thereafter), which interest shall be payable, at the option of the
Holder, either: (x) in cash or (y) in shares of Common Stock (with each share of Common Stock being valued based on the closing
price of the Common Stock on the principal market on which the Common Stock is either traded or quoted at such time on the date
immediately prior to the date on which the applicable interest payment is due and payable hereunder, or in the event the Common
Stock is not then traded or quotes on any principal market, at the price per share equal to the then current fair market value
of the Common Stock, as determined by an independent valuation expert selected jointly by the Company and the Holder, provided
that the Company shall pay any such valuation expenses.

 

3.
Conversion; Repayment.

 

(a)
The unpaid principal amount of this Note, together with any interest accrued but unpaid thereon, shall be converted into the securities
of the Company to be issued and sold at the closing of the Qualified Financing. Upon the conversion of this Note pursuant to this
Section 3, the Holder shall be entitled to receive such number and amount of the securities of the Company to be issued
upon such conversion equal to the quotient obtained by dividing (i) the unpaid principal amount of this Note (together with any
interest accrued but unpaid thereon) by (ii) the price paid for such securities in the Qualified Financing. The issuance of securities
pursuant to the conversion of this Note will be on, and subject to, the same terms and conditions applicable to the securities
issued in the Qualified Financing. For purposes of this Note, a “Qualified Financing” means an equity funding
of the Company yield proceeds to the Company of not less than $10,000,000.

 

(b)
In the even that the Qualified Financing has not occurred on or prior to the Maturity Date, the Company shall repay this Note
(together with any interest accrued but unpaid thereon) immediately following the Maturity Date.

 

4.
Mechanics of Conversion.

 

(a)
In the event that this Note is converted pursuant to Section 3, the Holder shall surrender this Note, duly endorsed, to the Company
promptly following the closing of the Qualified Financing, and the Note shall thereupon be canceled. As soon as practicable following
surrender of this Note (or a duly executed affidavit of loss with any indemnity reasonably requested by the Company) and at its
expense, the Company will take such steps, and execute and deliver such agreements, documents and instruments, as may be reasonably
necessary to issue and deliver to the Holder a certificate or certificates representing the securities of the Company to which
the Holder is entitled upon such conversion.

 

(b)
The Holder acknowledges that the conversion of this Note pursuant to Section 3 into the securities of the Company to be
issued in the Qualified Financing may require the Holder’s execution of certain agreements relating to the purchase and
sale of such securities, as well as registration rights, rights of first refusal and co-sale rights, rights of first offer and
voting rights, if any, relating to such securities (collectively, the “Financing Arrangements”). The Holder
agrees to execute all of the Financing Agreements in connection with the Qualified Financing as may be reasonably requested by
the Company.

 

    	 	2	 

    	 

    

 

5.
Termination of Rights. Upon payment in full of this Note, or conversion of this Note in accordance with Section
3, all rights with respect to this Note shall terminate, whether or not this Note has been surrendered for cancellation.

 

6.
Events of Default. In case an Event of Default shall occur, then upon demand by the Holder (which demand shall not
be required in the case of an Event of Default under Sections 6.1(b) or (c) of the Purchase Agreement), the entire outstanding
principal amount, plus accrued and unpaid interest thereon, of this Note shall become immediately due and payable in the manner
and with the effect provided in the Purchase Agreement and this Note.

 

7.
Events of Default – License; Commercial Transaction.

 

(a)
In connection with the issuance of this Note, the Company shall deposit with Holder certain MRI imaging data and related information
in the Company’s possession (the “Subject Data”). The Subject Data will include full resolution images,
all information in the Company’s possession that is used or useful in connection with the Subject Data, including all information
related to causes or changes in the MRI imaging data. Effective upon an Event of Default, then Holder, without any further action
on the part of the Company or Holder, the Company hereby grants Holder a perpetual, irrevocable, world-wide, non-exclusive, royalty-free,
fully paid-up, sublicensable, transferable license to install, execute, perform, display, transmit, distribute (directly or indirectly),
prepare derivative works of, and otherwise use the Subject Data. The license granted to Holder pursuant to this Section 7 shall
survive the termination or repayment of this Note (but shall only be effective from and after the occurrence of an Event of Default).
The license granted hereunder shall not be deemed to be an election of remedies and shall not effect Holder’s other rights
under this Note as a creditor or otherwise, to receive payment of the obligations owing hereunder.

 

(b)
In the event that the Qualified Financing does not occur on or prior to the Maturity Date, the Company and the Holder shall work
together in good faith to develop a commercial relationship pursuant to which the Company and Holder will develop an artificial
intelligence platform, making use of the Subject Data, for use in the pharmaceutical / drug discovery industry.

 

8.
Transfer; Successors and Assigns. The Holder may not sell, assign, pledge, dispose of or otherwise transfer this Note
or any interest herein without the prior written consent of the Company, which shall not be unreasonably withheld; provided,
however, a Holder that is a partnership, corporation, trust, joint venture, unincorporated organization or other entity
may transfer this Note to any person that owns all (but not less than all) of the issued and outstanding voting securities of
such entity without the prior written consent of the Company. Subject to the preceding sentence, this Note may be transferred
only upon surrender of the original Note (or affidavit of loss with any indemnity reasonably requested by the Company) for registration
of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company.
Thereupon, a new note for the same principal amount and interest will be issued to, and registered in the name of, the transferee.
Interest and principal are payable only to the registered Holder. The terms and conditions of this Note shall inure to the benefit
of and be binding upon the respective successors and assigns of the parties.

 

    	 	3	 

    	 

    

 

9.
Security Interest. This note is secured by the Subject Data.

 

10.
Governing Law. This Note shall be governed by and construed in accordance with the internal laws of the State of California
without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

 

11.
Notices. All notices required or permitted hereunder shall be given in accordance with Section 7.5 of the Purchase
Agreement.

 

12.
Amendments and Waivers. The terms and provisions of this Note may be amended or modified, and any provision hereof
may be waived, only with the written consent of the Company and the Holder.

 

13.
Headings. The headings in this Note are for purposes of reference only, and shall not limit or otherwise affect the
meaning hereof.

 

14.
Cost of Collection. In the event that Holder is required to take legal or other action to enforce its rights or
obtain collection under this Note, the Company shall pay the Holder hereof reasonable costs of collection, or enforcement of the
terms hereof, including attorneys’ fees.

 

15.
Maximum Payments. Nothing contained herein shall be deemed to establish or require the payment of a rate of interest
or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid
or other charges hereunder exceed the maximum permitted by such law (such as, without limitation, the usury laws), any payments
in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company,
or if no further amounts are owed by the Company to the Holder, shall be refunded to the Company. The Company hereby irrevocable
consents to the reformation of this Note, as may be necessary by a court of law, so as to enable enforcement of this Note pursuant
to summary judgment or summary proceeding. For avoidance of doubt, in the event that, for any reason, a finding by a court having
jurisdiction over this Note is made that limits enforceability as a result of excessive interest or other origination or investment
banking fees pursuant to the laws of any jurisdiction, then, such defense shall not be deemed to bar a summary proceeding or summary
judgment on the Note but rather, the Note shall be fully and absolutely enforceable as to all principal and, the court having
jurisdiction shall, after an inquest, have power to reform the Note so as to reduce interest amount to such amount as is immediately
enforceable pursuant to summary judgment or summary proceeding and grant such award, plus any legal or enforcement fees of the
Holder.

 

16.
Construction and Enforcement. Each party acknowledges that its legal counsel participated in the preparation of this
Note and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall
not be applied in the interpretation of this Note to favor any party against the other. This Note reflects an investment made
by the Holder or its assignor to the Company.

 

[remainder
of page intentionally left blank; signature page follows]

 

    	 	4	 

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Note to be duly executed and delivered.

 

	MATEON THERAPEUTICS, INC.	 
	 	 	 
	By:	/s/
    Vuong     Trieu	 
	Name:
    	Vuong
    Trieu	 
	Title:
    	CEO	 

 

[Signature
Page to Convertible Promissory Note]

 

    	 	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}]]